Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase

Molecular Cancer Therapeutics

Volumn 4, Issue 5, 2005, Pages 835-842

  Ramos Nino, Maria E ^a   Vianale, Giovina ^b   Sabo Attwood, Tara ^a   Mutti, Luciano ^c   Porta, Camilo ^d   Heintz, Nicholas ^a   Mossman, Brooke T ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CHIETI   (Italy)

^c IRCCS   (Italy)

^d Matteo Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RANPIRNASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DNA STRAND BREAKAGE; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MESOTHELIOMA; PREDICTION; PRIORITY JOURNAL; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIGENS, POLYOMAVIRUS TRANSFORMING; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPSY; CASPASES; DNA DAMAGE; ENZYME INHIBITORS; G0 PHASE; G1 PHASE; HUMANS; IN SITU NICK-END LABELING; MESOTHELIOMA; PHOSPHORYLATION; PLEURAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RIBONUCLEASES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 20044374361     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0243     Document Type: Article

References (29)

1. Mossman B, Gee J. Asbestos related disease. N Engl J Med 1989;320: 1721-30.
2. Carbone M, Rdzanek MA. Pathogenesis of malignant mesothelioma. Clin Lung Cancer 2004;5 Suppl 2:S46-50.
3. Mossman B, Bignon J, Corn M, Seaton A, Gee J. Asbestos: scientific developments and implications for public policy. Science 1990;247: 294-301.
4. Klein G, Powers A, Croce C. Association of SV40 with human tumors. Oncogene 2002;21:1141-9.
5. Pass HI, Donington JS, Wu P, et al. Human mesotheliomas contain the simian virus-40 regulatory region and large tumor antigen DNA sequences. J Thorac Cardiovasc Surg 1998;116:854-9.
6. McDonald J, Wagner A. The epidemiology of mesothelioma in historical context. Eur RespirJ 1996;9:1932-42.
7. Vogelzang NJ. Multimodality therapy in mesothelioma: role of chemotherapy. Thorac Surg Clin 2004;14:531-42.
8. Pistolesi M, Rusthoven J. Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies. Chest 2004; 126: 1318-29.
9. Martino D, Pass HI. Integration of multimodality approaches in the management of malignant pleural mesothelioma. Clin Lung Cancer 2004;5: 290-8.
10. Leland PA, Raines RT. Cancer chemotherapy-ribonucleases to the rescue. Chem Biol 2001;8:405-13.
11. Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002;20:274-81.
12. Iordanov MS, Ryabinina OP, Wong J, et al. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res 2000;60:1983-94.
13. Smith MR, Newton DL, Mikulski SM, Rybak SM. Cell cycle-related differences in susceptibility of NIH/3T3 cells to ribonucleases. Exp Cell Res 1999;247:220-32.
14. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
15. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3 kinase/Akt and mitogen activated protein kinase pathways. Proc Natl Acad Sci U S A 2001;98: 247-52.
16. Muscella A, Elia MG, Greco S, Storelli C, Marsigliante S. Activation of P2Y2 receptor induces c-FOS protein through a pathway involving mitogen-activated protein kinases and phosphoinositide 3-kinases in HeLa cells. J Cell Physiol 2003;195:234-40.
17. Scapoli L, Ramos-Nino ME, Martinelli M, Mossman BT. Src-dependent ERK5 and Src/EGFR-dependent ERK1/2 activation is required for cell proliferation by asbestos. Oncogene 2004;23:805-13.
18. Scapoli L, Ramos-Nino M, Martinelli M, Mossman B. Src-dependent ERK5 and Src/EGFR-dependent ERK1/2 activation is required for cell proliferation by asbestos. Oncogene 2004;23:805-13.
19. BeruBe K, Quinlan T, Fung H, et al. Apoptosis is observed in mesothelial cells after exposure to crocidolite asbestos. Am J Respir Cell Mol Biol 1996;15:141-7.
20. Goldberg J, Zanella C, Janssen Y, et al. Novel cell imaging approaches show induction of apoptosis and proliferation in mesothelial cells by asbestos. Am J Respir Cell Mol Biol 1997;17:265-71.
21. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-7.
22. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001;26:657-64.
23. Leslie NR, Downes CP. PTEN: the down side of PI 3-kinase signalling. Cell Signal 2002;14:285-95.
24. Aldieri E, Orecchia S, Ghigo D, et al. Simian virus 40 infection down-regulates the expression of nitric oxide synthase in human mesothelial cells. Cancer Res 2004;64:4082-4.
25. Carbone M, Fisher S, Powers A, Pass HI, Rizzo P. New molecular and epidemiological issues in mesothelioma: role of SV40. J Cell Physiol 1999;180:167-72.
26. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002;29:2-17.
27. Carbone M, Pass HI, Miele L, Bocchetta M. New developments about the association of SV40 with human mesothelioma. Oncogene 2003;22:5173-80.
28. Yu Y, Alwine JC. Human cytomegalovirus major immediate-early proteins and simian virus 40 large T antigen can inhibit apoptosis through activation of the phosphatidylinositide 3′-OH kinase pathway and the cellular kinase Akt. J Virol 2002;76: 3731-8.
29. Cacciotti P, Libener R, Bette P, et al. SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci U S A 2001;98:12032-7.